Kaposi Sarcoma Market Size (2024 - 2029)

Kaposi Sarcoma Market Analysis

The Kaposi sarcoma market is poised to grow at a CAGR of 7% during the forecast period.

Many studies have revealed that the virus that causes COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), encoded proteins, and various anti-infection medicines have promoted lytic reactivation of Kaposi Sarcoma-associated herpesvirus (KSHV). For instance, according to the study published in Communication Biology in June 2021, researchers discovered that SARS-CoV-2 might cause lytic reactivation of Kaposi Sarcoma. They also discovered that two medications, Nafamostat and Azithromycin, increased the generation of mature virions, potentially generating lytic reactivation of Kaposi Sarcoma. Hence, SARS-COVID-19 treatment may induce Kaposi Sarcoma to impact the market growth during the pandemic significantly. However, the industry has been recovering well since the restrictions were lifted and declining in COVID-19 infection cases. Over the last two years, the market recovery has been led by the high prevalence of Kaposi Sarcoma and new product launches.

The growing prevalence of Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures who are more susceptible to Kaposi Sarcoma. These are the major factors attributing to the growth of the Kaposi Sarcoma market. According to the study published in Cancers in November 2021, Kaposi Sarcoma is more common in males who have sex with men (MSM) and in specific locations of the world, such as Sub-Saharan Africa or countries bordering the Mediterranean. The incidence of Kaposi Sarcoma in Sub-Saharan Africa varies according to the area. In Uganda, where the frequency is already high in early childhood, the annual prevalence is 50%. In addition, per the Cancer Get updates in January 2022, in the United States, about one in every 200 transplant recipients gets Kaposi Sarcoma. In 2020, an estimated 34,270 persons were diagnosed with Kaposi Sarcoma worldwide. Thus, the growing prevalence of Kaposi Sarcoma in African countries is expected to drive the demand for Kaposi sarcoma diagnosis and treatment, thereby boosting the market's growth.

Furthermore, a growing number of organ transplants is expected to support market growth. According to the Health Resources and Service Administration, in March 2022, around 40,000 organ transplants were done in the United States in 2021, with 105,800 people on the waiting list for an organ transplant. Thus, an increase in organ transplants is expected to increase the risk of getting affected with Kaposi sarcoma to boost market growth over the forecast period.

However, a shortage in the supply of drugs due to a wide demand-supply gap and the high cost of the treatment and diagnosis of Kaposi Sarcoma will impede the growth of the global market.

Kaposi Sarcoma Industry Segmentation

As per the scope of the report, Kaposi sarcoma (KS) is cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV). The market is segmented by type (epidemic (AIDS-associated) Kaposi sarcoma, classic (Mediterranean) Kaposi sarcoma, endemic (African) Kaposi sarcoma, iatrogenic (transplant-related) Kaposi sarcoma), product (diagnostics, treatment), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.